Healthcare distributors that handle controlled substances and list 1 chemicals
are subject to DEA and state requirements under state and federal Controlled
Substances Acts. These requirements are usually aimed at preventing diversion
and other criminal activities.
Drug Enforcement Administration (DEA)
- HDMA Comments on DEA's Proposed Rule to Place Carisoprodol into Schedule IV - December 17, 2009
- Cover Letter to HDMA Comments to FDA on the REMS for Certain Opioids - June 30, 2009
- HDMA comments on the FDA REMS for Certain Opioids - June 30, 2009
- HDMA Comments on DEA's Interim Final Rule Implementing the Ryan Haight Online Pharmacy Consumer Protection Act of 2008 - June 5, 2009
- HDMA Comments to DEA on Pharmaceutical Take-Back Programs - March 23, 2009
- HDMA Industry Compliance Guidelines - November 13, 2008
- DEA Letter on HDMA Industry Compliance Guidelines: Reporting Suspicious Orders
and Preventing Diversion of
Controlled Substances - November 13, 2008
- DEA Letter on Form 106 - October 27, 2008
- DEA Letter on Registration Requirements for Handlers of Iodine - April 29, 2008
- HDMA Comments on the Notice of Proposed Rulemaking Regarding DEA Form 222 - Feb. 8, 2008
- Cover letter to HDMA Comments on DEA Self-Certification Proposed Rule-
Nov. 26, 2007
- Attachment: HDMA Comments on DEA Self-Certification Proposed Rule-
Nov. 26, 2007
- DEA Letter on Import and Production Quotas rule - July 11, 2007
- DEA Letter on Regulation of Iodine - July 2, 2007
- DEA Letter on Theft of Hydrocodone Combination Products - June 22, 2007
- DEA Letter on LIst I and List II Chemical Importation/Exportation - April 9, 2007
Related Activities
Click here for more information on the
Controlled Substance Ordering System.
Contacts
Anita Ducca
Senior Director, Regulatory Affairs
703-885-0240
aducca@hdmanet.org
John Howells
Senior Director, Industry Relations
703-885-0277
jhowells@hdmanet.org
Dan Bellingham
Director, State Government Affairs
703-885-0236
dbellingham@hdmanet.org
|
denotes HDMA members-only content.